

PSJ2 Exh 166

OPUSHEALTH
A Division of Cegedim Relationship Management

Opana® ER Savings Card Program Promotional Response & ROI Analysis

September 2010 through March 2012 (Inclusive of Pre-Period)

June 26, 2012



©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 0



Key Findings

OPUSHEALTH
A Division of Cardinal Health

- Analyzing the overall program 13 months post launch (March 2011 through March 2012), the savings card program ROI is 28.9 to 1.
- During three months since December 2011 analysis period, 5,465 new patients and 1,067 new prescribers were acquired through Savings card program.
- 61.7% of Opana ER NRx volume came from Pain prescribers and had the highest average gain of 45.9 NRx per prescriber over their control counterparts. This is an increase of 9.6 NRx from the December 2011 report period.
- Patient and HCP Print-on-Demand tactics demonstrated the highest average NRx volume gain of 4.7 NRx per participating prescriber per month over the control group compared to other tactics.
- Patient Print-on-Demand card users have the highest average card use of 3.26 times, with 61% of patients using their cards two or more times.



©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 1



Executive Summary

OPUSHEALTH
A Division of Cegedim Relationship Management

Program Impact:

Number of Prescribers Measured	Incremental Change*	
	NRx Share	NRx Volume**
1,691	6.9%	3,223/month

* Incremental is pre versus post period and participating prescribers versus control group

* Pre-program period is September 2010 through February 2011

** Including total participating prescribers per month across all tactics

- All tactics combined, the Opana ER Savings Card Program participants demonstrated statistically significant incremental gains in NRx share and volume versus the control group.
 - NRx share incremental change of **6.9** share points, an increase of **1** share points from the December 2011 report period.
 - Incremental NRx volume of **3,223** additional NRxs per month, an increase of **445** additional NRxs from the December 2011 report period.
 - Pain specialty** participating prescribers accounted for 61.7% of Opana ER NRx volume in the promotional period and **had the highest average NRx gain of 45.9 NRx per prescriber** over their control counterparts.
 - Print-on-Demand** participating prescribers (n=649) had the largest NRx share gain of **9.6 share points** over their control counterparts.
 - In March 2012, HCP and Patient Print-on-Demand participating prescribers demonstrated the highest Opana ER NRx volume gain per participant prescriber per month over their control counterparts of **4.7 additional incremental NRx**.
- In March 2012, Savings card program NRx claims comprised 7.9% of Opana ER NRxs nationwide, an increase of 1% from the December 2011 report period.

 **endo**
Pharmaceuticals

©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 2

 **opana ER**
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 15 mg, 20 mg, 30 mg

Executive Summary

OPUSHEALTH
A Division of Capgemini Relationship Management

ROI:

- Analyzing the 13 months for the Savings card program (March 2011 through March 2012) has realized an **ROI of 28.9 to 1**. Meaning, that for every dollar spent on this program, \$28.9 in brand revenue was earned*.

Total program revenue	\$65,670,533
Program costs (all including patent benefit and pharmacy fees)	\$ 2,270,596
ROI (Revenue / Costs) ¹	28.9:1

¹ The actual ROI value was rounded to 1 decimal point.

*Based on the Savings card program cost and blended Opana ER WAC price.



©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 3



Executive Summary

OPUSHEALTH
A Division of Cegedim Relationship Management

Program Response- Patients:

- Through March 2012, patients using a Pharmacy Direct card, Patient Starter Kit Copay Savings card, Healthcare professional (HCP) or Patient Print-on-Demand card totaled **25,647*** patients with **25,376** unique patients. This is an increase of **5,465** new patients from the December 2011.
- 20,230** or **78.9%** of patients were using the Patient Starter Kit Copay Savings card.
- 4,157** or **16.2%** of patients were using the HCP or Patient Print-on-Demand card.
- 1,260** or **4.9%** of patients were using the Pharmacy Direct card. The number of patients using the Pharmacy Direct card increased by **41.7%** compare to December 2011 analysis period.
- Of the patients who began using their cards in April 2011, **64%** had used their card more than once among all tactics combined. Participating patients who used the **Patient Print-on-Demand card** had the highest usage with **61%** using their card two or more times and had the average card usage rate of **3.26** times.

Program Response- Prescribers:

- As of the end of March 2012, unique participating prescribers totaled **6,800** with **83.3% being targets** and **15.5% non-targets**.
 - 5,283** or **59.3%** of cumulative prescribers had patients using the Patient Starter Kit Copay Savings card.
 - 2,916** or **32.4%** of prescribers had patients using either a Patient or HCP Print-on-Demand card with **the majority (76%) using the Patient Print-on-Demand card**.
 - 739** or **8.3%** of cumulative prescribers had patients using the Pharmacy Direct card.
- Participating prescribers represented **16.3%** of national Opana ER prescribers (based on IMS Xponent) and **16.7%** of Opana ER's target universe.



*Patients can use multiple cards therefore count of patients in individual card groups may exceed unique totals.
©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 4
Source: OPUS Health matched to IMS Xponent



Agenda

OPUSHEALTH
A Division of Cegedim Relationship Management

NRx Share and Volume

ROI

Program Summary

Appendix



©2012 Cegadim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 5




Among all participating prescribers, Opana ER average NRx share increased by **9.5** share points during the promotional period versus the pre-period, while control increased 2.6 share points.

OPUSHEALTH
A Division of Capgemini Relationship Management

Matched Participants = 1,691
Control = 1,691

Opana ER NRx Share: Participating Prescribers vs. Control



	All Tactics Combined (N = 1,691)			Patient Starter Kit CapRx Case (N = 1,143)			*Print-on-Demand (N = 658)			Pharmacy Direct (N = 158)		
Prescriber Segment	Avg Pre NRx Share	Avg Post NRx Share	Change	Avg Pre NRx Share	Avg Post NRx Share	Change	Avg Pre NRx Share	Avg Post NRx Share	Change	Avg Pre NRx Share	Avg Post NRx Share	Change
Participants	16.4%	26.9%	10.5%	17.4%	26.3%	8.9%	18.5%	30.3%	11.7%	18.0%	27.3%	9.3%
Control	16.4%	19.0%	2.6%	17.4%	18.3%	0.9%	18.5%	20.2%	1.7%	18.4%	19.8%	1.4%
NRx Share Gain			8.9%			7.0%			9.6%			7.4%

endo
Pharmaceuticals

* Print-on-Demand includes both Patient and HCP tactics

©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 6

opana ER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 20 mg, 40 mg


Source: IMS Xponent

Among all participating prescribers, Opana ER average NRx volume increased 3,591 NRx per month during the promotional period versus the pre-period, while control increased 368 NRx.

OPUSHEALTH
A Division of Capgemini Relationship Management

Matched Participants = 1,691
Control = 1,691

Opana ER NRx Volume: Participating Prescribers vs. Control



Prescriber Segment	All Tactics Combined (N = 1,691)			Patient Starter Kit Copy Card (N = 1,143)			*Print-on-Demand (N = 649)			Pharmacist Direct (N = 158)		
	Avg Pre NRx Volume	Avg Post NRx Volume	Change	Avg Pre NRx Volume	Avg Post NRx Volume	Change	Avg Pre NRx Volume	Avg Post NRx Volume	Change	Avg Pre NRx Volume	Avg Post NRx Volume	Change
Participants	1,462	7,053	5,591	2,976	5,677	2,701	1,650	3,705	2,055	476	878	402
Control	1,462	3,810	2,348	2,959	3,664	705	1,622	1,726	104	462	412	50
NRx Volume Gain		3,223			2,701			1,079			388	

endo
Pharmaceuticals
Source: IMS Xponent

* Print-on-Demand combines Patient and HCP tactics

©2012 Cephalon. All rights reserved. Contains proprietary and confidential information. Do not distribute. 7


opana ER
(oxycodone HCl) ER
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 20 mg, 40 mg

Prescribers with patients who participated in Print-on-Demand tactics demonstrated a **4.68 NRx incremental gain** over their control counterparts and have the highest average monthly Opana ER NRx volume gain of **3.23** per participating prescriber over the control group.

OPUSHEALTH
A Division of Capgemini Relationship Management

Matched Participants = 1,691
Control = 1,691

****Prescriber Avg Opana ER NRx Volume Difference between Participant and Control**
(March 2011 - March 2012)



Tactic	Avg Monthly Participant NRx Gain (March 2011 - March 2012)
*Print-on-Demand	3.23
Patient Starter Kit	2.56
Pharmacy Direct	2.27

* Print-on-Demand combines Patient and HCP Print-on-Demand tactics

* *There is potential double counting, since a prescriber can be in more than one group.

endo
Pharmaceuticals
Source: IMS Xponent

Note: NRx gain calculated from matched pair differences of participant versus control within tactic and in the given month.

©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 8


OPANa ER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 20 mg, 40 mg

Pain specialists accounted for **61.7%** of Opana ER NRx volume in the promotional period and had an incremental NRx gain of **45.9** NRx per prescriber versus control.

OPUSHEALTH
A Division of Capgemini Relationship Management

Matched Participants = 1,691
Control = 1,691

Participant Opana ER NRx Volume and Avg. NRx by Prescriber by Specialty



Specialty	Number of Prescribers	Avg NRx per Participant Prescriber (Mar 2011-Mar 2012)	Avg NRx per Control Prescriber (Mar 2011-Mar 2012)	Avg NRx Gain
NP/PA	127	52.2	13.8	38.4
Neurology	15	44.1	8.6	35.5
Other	782	26.9	13.1	13.9
PCP	272	24.9	13.1	11.7
Pain	495	114.3	68.4	45.9

Total participating prescriber NRx volume: 91,691 NRx

endo
Pharmaceuticals
Source: IMS Xponent

©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 9


opana ER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 20 mg, 40 mg

In March 2012, Savings Card Program claims comprised 8.0% of Opana ER NRxs nationwide, 1% increase since the December 2011 analysis time period. Participant prescribers represent 16.3% of national Opana ER prescribers, 0.6 % increase since the December analysis time period.

OPUSHEALTH
A Division of Capgemini Relationship Management

Participant Prescribers = 6,803
All Prescribers = 41,733

Breakdown of OPUS vs. National NRx Claims - Opana ER
(March 2011 - March 2012)



Note: OPUS claims and participant prescribers counts represent data in OPUS health database. National claims represent Opana claims and all prescribers represent prescribers who prescribe Opana in IMS Xponent data.

endo
Pharmaceuticals
Source: OPUS Health and IMS Xponent

©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 10

opana ER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg • 12 mg • 20 mg • 40 mg

OPUSHEALTH
A Division of Cegedim Relationship Management

NRx Share and Volume

ROI

Program Summary

Appendix



©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 11



ROI Calculation Based on Paired Differences

OPUSHEALTH
A Division of Catalyst Relationship Management

*Based on paired differences
(Test prescribers versus control prescribers for each matched pair)*

1 Monthly Rx difference (Test prescriber NRx-Control prescriber NRx) ¹	3.16
2 Prescribers per month (weighted average with all prescribers)	2,819
3 Program months	13
4 Incremental NRx (line 1 x line 2 x line 3) ²	115,643
5 Net NRx value (Blended price of actuals ³)	\$ 567.87
6 Total program revenue (line 4 x line 5) ⁴	\$ 65,670,533
7 Program costs (all including patient benefit and pharmacy fees)	\$ 2,270,596
8 ROI (Revenue / Costs) ⁵	28.9:1

¹ The number of Test/Control pairs per month are based on the month Test prescriber has patient's script redeemed with the Savings card.

² The number in line 4 is different from the result of calculations (line 1 x line 2 x line 3) due to the rounding of the numbers in line 1 and 2. The actual monthly Rx difference is 3.15503121651296 and prescribers per month is 2819.49798420629.

³ WAC price per pill in conjunction with the % allocation of Opana ER pills based on strength (see slide 27 for details).

⁴ The number in line 6 is different from the result of calculations (line 4 x line 5) due to the rounding of the numbers in line 4 and 5. The actual incremental NRx is 115642.854015861 and net NRx value is 567.873682905078.

⁵ The actual ROI value was rounded to 1 decimal point.



Sources: OPUS Health Database of program transactions (March 2011 through March 2012) and IMS Xponent (September 2010 through March 2012 inclusive of pre-period)

©2012 Catalyst. All rights reserved. Contains proprietary and confidential information. Do not distribute. 12



Program Costs (March 2011 through March 2012)

OPUSHEALTH
A Division of Cegedim Relationship Management


- Cegedim program direct costs include: program setup, monthly management fees, materials production cost, electronic transaction and pharmacy check processing, live pharmacy direct notice and pharmacy postage, manual claim processing. Program redemption costs include: patient and pharmacy incentive from March 2011 through March 2012.

Cegedim Program Direct Costs \$ 498,528
+
Program Redemption Costs \$ 1,772,068
=
Total Direct Program Costs \$ 2,270,596




©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 13





NRx differences observed in the program period between test and control prescribers indicate incremental gains in prescribers with participating savings card patients.

OPUSHEALTH
A Division of Capgemini Relationship Management



	Sep-10	Oct-10	Nov-10	Dec-10	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11	Jan-12	Feb-12	Mar-12
Program Prescribers (all incl. w/ IDs)							708	1,382	2,016	2,285	2,643	2,541	3,082	3,219	3,406	3,228	3,780	3,643	3,395
Prescriber pairs in statistical tests							29	713	825	281	671	312	431	429	531	575	545	545	523
Participant NRx							340	1,306	2,201	2,631	2,757	3,438	3,963	4,402	4,840	5,252	5,712	4,796	4,623
Control NRx or extended NRx							145	844	1,362	1,900	1,291	1,455	1,243	1,651	1,656	1,536	1,908	1,675	1,503
Participant NRx	3,067	3,266	3,196	3,641	3,630	3,510	1,804	4,709	5,011	6,099	6,087	7,221	7,517	7,822	8,119	8,034	8,837	7,715	7,456
Control NRx	2,940	3,122	3,454	3,815	2,988	3,614	4,185	3,742	3,941	4,021	3,705	3,597	3,731	3,870	4,001	2,551	3,803	3,414	2,660



©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 15

Source: OPUS Health and IMS Xponent



Agenda

OPUSHEALTH
A Division of Cegedim Relationship Management

NRx Share and Volume

ROI

Program Summary

Appendix




©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 16



Through March 2012, cumulative participating patients totaled *25,647 increasing 5,708 patients since the December analysis period. 78.9% used the Patient Starter Kit Co-pay Savings card.

OPUSHEALTH
A Division of Capgemini Relationship Management

Cumulative Participating Patients by Month and Group
(March 2011 - March 2012)




endo
Pharmaceuticals
Source: OPUS Health

* Patients can use multiple cards so individual card groups may exceed unique totals
Total unique patients through March 2012 = 25,376 with 269 using multiple cards

opanax
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 15 mg, 20 mg, 30 mg

Of all participating patients who started using cards in April 2011, 64% have used it more than once. Patient Print-on-Demand card users averaged the highest usage of 3.26, with 61% using their cards two or more times.

OPUSHEALTH
A Division of Capgemini Relationship Management



Program Name	Number of distinct patients	Average Card Use	# Of patients used the card twice or more	% Of patients used the card twice or more	# Of patients used the card three times or more	% Of patients used the card three times or more
HCP Print on Demand	1,105	2.33	575	52%	340	31%
Patient Print on Demand	3,062	3.26	1,849	61%	1,308	43%
Patient Starter Kit Copay Card	20,230	3.03	11,806	59%	8,338	41%
Pharmacy Direct	1,200	2.73	479	40%	423	35%


endo
Pharmaceuticals
Source: OPUS Health

©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 18

opana
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg

As of March 2012, **59.3%** of participating prescribers had patients using a Patient Starter Kit Co-pay Savings card. **24.9%** had patients using a Patient Print-on-Demand card.

OPUSHEALTH
A Division of Capgemini Relationship Management



endo
Pharmaceuticals
Source: OPLS Health


Note: There is potential double counting, since a prescriber can be in more than one group.
Total unique prescribers through March 2012 = 6,800 with 1,708 using multiple cards.

opanaxER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg - 12 mg - 20 mg - 40 mg

©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 19

As of March 2012, unique participating prescribers totaled 6,800 prescribers, with 83.3% coming from targets.

OPUSHEALTH
A Division of Capgemini Relationship Management



endo
Pharmaceuticals


©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute.

opanax ER
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg - 12 mg - 20 mg - 40 mg

Of the top 10 states by total adjudications, MD had the most co-pays under \$30. TN had the most over \$100. FL had the highest number of adjudications with the lowest average co-pay before benefit at \$82.37 (of the top 10 states).

OPUSHEALTH
A Division of Capgemini Relationship Management

Adjudications for Top 10 states
(March 2011 - March 2012)



Number of patients = 14,847

endo
Pharmaceuticals
Source: OPUS Health

Note: co-pays are BEFORE benefit
©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 21

OPANAPEN
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg, 10 mg, 20 mg, 30 mg, 40 mg

Agenda

OPUSHEALTH
A Division of Cegedim Relationship Management

NRx Share and Volume

ROI

Program Summary

Appendix



©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 22



Analysis Background

OPUSHEALTH
A Division of Cardinal Relationship Management

ROI Methodology:

- The ROI methodology uses a paired samples t-test which compares each test and control prescriber pair. Incremental NRx in each month is the average NRx difference between each pair test prescriber (those with participating patients) and respective control prescriber. Statistically significant differences are multiplied by the total number of prescribers participating in the program in the given month and added across the program months.

Participating Prescribers:

- A total of 6,800 unique prescribers who participated in the Opana ER Savings Card program as of March 2012 were identified in the OPUS card program database (based on prescriber's DEA identification number). Of these, 6,530 had at least 1 Opana ER TRx in the analysis period in IMS Xponent, and therefore could be measured.

Control Prescribers:

- A control group was established retrospectively as one was not established prior to the rollout of the program in March 2011. 35,455 prescribers were identified in IMS Xponent as having prescribed at least 1 Opana ER TRx in the analysis period and did not have a card redemption for the Opana ER Savings Card program in the promotional period. These prescribers could then be used for the control group pool.

Market definition:

- Opana ER, Embeda, Oxycontin, Nucynta, Nucynta ER, Kadian, Exalgo, Avinza

Time Period:

- Pre-Period: September 2010 through February 2011
- Promotion-Period: March 2011 through March 2012

 **endo**
Pharmaceuticals

©2012 Cardinal. All rights reserved. Contains proprietary and confidential information. Do not distribute. 23

 **opana^{ER}**
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg • 12 mg • 20 mg • 40 mg

Program Overview and Objectives

OPUSHEALTH
A Division of Cardinal Health

The Prescriber Promotional Response Analysis measures the impact of the Opana ER Patient Experience Program Copay Card on prescribers that have patients using the Opana ER Copay cards in their practices. The analysis is for the 13 month period ending March 31, 2012.

Program Overview:

- The Opana ER Patient Experience Program was launched in March, 2011 with the following components:
 - In Office Patient Savings Card contained in the Program Starter Kit
 - Patient Print-on-Demand enables patients to visit the Opana ER website and download and print a copay card
 - Prior to downloading a card, patients are presented with optional enrollment into the CRM program and then receive a Welcome Email
 - The Pharmacy Direct program generates a copay card via fax to the pharmacy for patients who have not previously used a copay card.
- The HCP Print on Demand program allowed prescribers to print up to 10 copay cards from the Opana ER site to distribute to patients.

Program Objective:

- Increase NRx share and volume among participating prescribers.




©2012 Cardinal. All rights reserved. Contains proprietary and confidential information. Do not distribute. 24



Control Group Selection

OPUSHEALTH
A Division of Capgemini Relationship Management



**Includes all participating prescribers with identifiable DEAs

©2012 Cogadim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 25



Opana ER Net Price Assumptions

OPUSHEALTH
A Division of Capgemini Relationship Management

Product	Strength	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Average % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx
Opana ER		Mar-11	Mar-11	Mar-11	Mar-11	Apr-11	Apr-11	Apr-11	Apr-11	May-11	May-11	May-11	May-11
OPANA ER END 072006	300G	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44
OPANA ER END 072006	300G	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72
OPANA ER END 072006	300G	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74
OPANA ER END 072006	300G	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90
OPANA ER END 072006	300G	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24
Weighted price per Trx for Opana ER					\$661.65				\$661.65				\$666.44

Product	Strength	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Average % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx
Opana ER		Jul-11	Jul-11	Jul-11	Jul-11	Aug-11	Aug-11	Aug-11	Aug-11	Sep-11	Sep-11	Sep-11	Sep-11
OPANA ER END 072006	300G	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44
OPANA ER END 072006	300G	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72
OPANA ER END 072006	300G	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74
OPANA ER END 072006	300G	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90
OPANA ER END 072006	300G	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24
Weighted price per Trx for Opana ER					\$666.44				\$666.44				\$666.38

Product	Strength	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Average % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx	WAC Unit Price using FCB Data	Avg % Contribution	13 wk avg Pills per Trx as of 12/9*	Weighted price per Trx
Opana ER		Nov-11	Nov-11	Nov-11	Nov-11	Dec-11	Dec-11	Dec-11	Dec-11	Jan-12	Jan-12	Jan-12	Jan-12
OPANA ER END 072006	300G	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44	\$ 1.7999	5%	60.50	\$ 5.44
OPANA ER END 072006	300G	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72	\$ 3.4563	17%	60.80	\$ 35.72
OPANA ER END 072006	300G	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74	\$ 6.1391	26%	62.20	\$ 99.74
OPANA ER END 072006	300G	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90	\$ 8.8234	15%	64.90	\$ 85.90
OPANA ER END 072006	300G	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24	\$ 11.5167	37%	77.50	\$ 330.24
Weighted price per Trx for Opana ER					\$666.38				\$666.38				\$666.40



* WAC unit price per pill strength, average % of strength contribution and 13 weeks average pills per Trx were provided by Endo.

©2012 Capgemini. All rights reserved. Contains proprietary and confidential information. Do not distribute. 26



EXTENDED RELEASE TABLETS
5mg - 12mg - 30mg - 60mg

Statistical Tests



- These statistical tests represent monthly pairwise differences for March 2011 through March 2012.
- A probability value of $\leq .05$ indicates a significant difference between test and control physicians.

Metric	Participant to Control Group Difference (Mean)	Participant to Control Group			Participant to Control Group			Participant to Control Group			Participant to Control Group			Minimum	Maximum	t-Value	DF	Probability
		LowerCL	Mean	UpperCL	StdDev	LowerCL	StdDev	UpperCL	StdDev	LowerCL	StdDev	UpperCL	StdDev					
NRxTotal	-9177	17826	20728	117338	118251	118445	118240	118443	0.0761	-11018	485.3	2423	21682	< .0001				
MarketNRxTotal	4122	38157	44283	231657	229542	233874	229538	23387	0.1563	-200.2	617.4	2536	21682	< .0001				
NRxShare	0.0629	0.058	0.0677	0.3686	0.3632	0.3701	0.3632	0.3701	0.00247	-1	1	25.43	21682	< .0001				
TRxTotal	-9177	17823	2073	117486	118359	118565	118397	118593	0.0792	-11018	485.3	242	21682	< .0001				
MarketTRxTotal	41316	38245	44388	232311	230159	234803	230156	234499	0.1567	-200.2	617.4	2537	21682	< .0001				
TRxShare	0.0627	0.0575	0.0675	0.3685	0.3632	0.3701	0.3632	0.3701	0.00247	-1	1	25.34	21682	< .0001				



©2012 Cepheid. All rights reserved. Contains proprietary and confidential information. Do not distribute. 27



OPUSHEALTH
A Division of Cegedim Relationship Management



Thank you.
For More Information, Contact
Corinne Snider, Account Manager
908.443.2523
corinne.snider@cegedim.com



endo
Pharmaceuticals

©2012 Cegedim. All rights reserved. Contains proprietary and confidential information. Do not distribute. 28



opana^{ER}
(oxycodone HCl)
EXTENDED RELEASE TABLETS
5 mg • 10 mg • 15 mg • 20 mg • 30 mg